Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 12/20 | 0.45 |
| ▸ | ACHE | P22303 | 12/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611459 | 0.80 | KCNH2 (0.52) | TSHRLMNATYRKCNH2TP53 | |
| SCHEMBL128571 | 0.80 | ESR1 (0.39) | TSHRLMNATYRRECQL | |
| SCHEMBL5075930 | 0.79 | TSHR (0.48) | TSHRLMNATYRKCNH2TP53 | |
| SCHEMBL7456580 | 0.78 | KCNH2 (0.59) | TSHRLMNATYRKCNH2TP53 | |
| SCHEMBL348623 | 0.78 | TSHR (0.52) | TSHRLMNATYRKCNH2TP53 | |
| SCHEMBL1773317 | 0.77 | ESR1 (0.54) | TSHR | |
| SCHEMBL3240627 | 0.77 | TAAR1 (0.33) | — | |
| SCHEMBL4580070 | 0.77 | SHBG (0.57) | TSHRLMNAKCNH2TP53ACHE | |
| SCHEMBL1611687 | 0.77 | KCNH2 (0.58) | TSHRLMNAKCNH2TP53NR1H4 | |
| SCHEMBL1803971 | 0.76 | ESR1 (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017199103-A1 | BENZAMIDE COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-11-23 | — | — | WO | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | claimed |
| EP-2013171-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE | MERCK SHARP & DOHME (GB) | 2013-05-15 | — | — | EP | claimed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | claimed |
| EP-2567940-A1 | Method for preparing clays having novel physical-chemical properties | Ecole De Biologie Industrielle (EBI) (FR) | 2013-03-13 | — | — | EP | claimed |
| US-8389547-B2 | Piperidines and related compounds for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2013-03-05 | — | — | US | claimed |
| CN-102584829-A | Pyrazole and pyrazine diketone derivative and application thereof | UNIV SHANDONG | 2012-07-18 | — | — | CN | claimed |
| US-6464902-B1 | CONDENSATION OF AT LEAST TWO PERYLENE MONOIMIDE-MONOANHYDRIDES WITH 1,3-PROPANEDIAMINE FORM THE IMIDES; PHOTOCONDUCTIVE IMAGING MEMBERS WITH THE MIXED PERYLENE DIMER PIGMENTS; ENVIRONMENTALLY ACCEPTABLE MIXTURES | XEROX CORPORATION | 2002-10-15 | — | — | US | claimed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | claimed |
| EP-0861878-B1 | Unsymmetrical perylene dimers | XEROX CORP (US) | 2001-10-24 | — | — | EP | claimed |
| US-6287738-B1 | CONTAINING PERYLENEBISIMIDE | XEROX CORPORATION | 2001-09-11 | — | — | US | claimed |
| EP-0861878-A1 | Unsymmetrical perylene dimers | XEROX CORPORATION (US) | 1998-09-02 | — | — | EP | claimed |
| EP-0826740-A1 | Symmetrical perylene dimers | XEROX CORPORATION (US) | 1998-03-04 | — | — | EP | claimed |
| US-5683842-A | CHARGE GENERATORS FOR IMAGES | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5645965-A | XEROGRAPHY, CHARGE GENERATING COMPOUNDS | XEROX CORPORATION (US) | 1997-07-08 | — | — | US | claimed |
| US-4472412-A | Control of fungi using phenylpropylammonium salts | BASF AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | claimed |
| US-4469881-A | [2-(p-t-Butylphenyl)ethyl]silanes and method of making the same | PETRARCH SYSTEMS INC. (US) | 1984-09-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | TSHR 3998/4885LMNA 2949/4885TYR 4532/4885 |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | TSHR 1108/4885LMNA 1955/4885TYR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.